FIAR addresses issues relevant to both the prevention and treatment of HIV and chronic hepatitis, as the need for prevention and treatment are inextricably bound. FIAR supports prevention efforts in resource poor settings. FIAR evaluates, in clinical trial settings, the "dietary supplements" many people living with HIV/AIDS and/or hepatitis C are using to help delay progression, offset antiretroviral side effects or extend structured treatment interruptions in order to evaluate their benefits, risks, limitations and costs to enable better-informed treatment decisions.

To accomplish these goals, FIAR

• periodically assembles community members, clinicians and others to develop concept sheets for clinical studies;
• identifies promising, non-patentable interventions (dietary supplements) for which preliminary evidence exists to support their use for a particular indication;
• designs and coordinates clinical studies to evaluate their use in delaying HIV disease, managing antiretroviral side effects and HIV symptoms, or extending the time of a treatment interruption, nationally and internationally;
• addresses the needs of people with HIV in wealthy and resource-poor areas;
• evaluates products and obtain independent laboratory analysis of supplements/interventions to be evaluated in a clinical study;
• disseminates information and clinical findings in peer-reviewed journals, newsletters and on the FIAR website;
• develops pilot projects for HIV prevention and/or treatment projects in resource poor nations.

FIAR, as a 501(c)(3) not-for-profit, does not accept pharmaceutical or nutriceutical industry funding and relies upon your generosity to continue its efforts.

home | background | purity/potency | side effects | links | contact